Topline results expected in 1Q calendar year 2025 Study is assessing the co-administration of bremelanotide and tirzepatide on reducing body weight Data will inform and support the Company's obesity programs using novel, long-acting and highly selective MC4R peptide and small molecule compounds for treating general obesity, weight loss management, and rare/orphan MC4R pathway diseases, including hypothalamic obesity CRANBURY, N.J. , Oct.
31, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced it has completed enrollment in the study entitled " BMT-801 , A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity." The study enrolled approximately twice the target of 60 patients at four US sites, primarily due to strong patient demand and efficiency of the clinical trial sites.
All patients in the study are expected to have completed all dosing and patient visits by the end of January 2025 , with topline data readout expected before the end of March 2025 . "We believe the study data will demonstrate that combination of an MC4R agonist, such as bremelanotide, with a glucagon-like peptide 1/gastric inhibitory polypeptide (GLP-1.